Alzamend Neuro (NASDAQ:ALZN), a clinical-stage biopharmaceutical company focused on developing novel products for neurological disorders, reported preliminary pharmacodynamic data on April 7, 2026, from a healthy-subject study evaluating its lead candidate, AL001.
The study, conducted at Massachusetts General Hospital, utilized Magnetic Resonance Spectroscopy (MRS) to analyze brain metabolite changes in six healthy subjects.
Participants received two weeks of blood-bioequivalent doses of AL001—a patented ionic crystal of lithium—versus traditional lithium carbonate.
According to the preliminary findings, AL001 demonstrated a trend toward the reduction of myo-inositol in 17 of 18 examined brain regions.
Myo-inositol is often utilized as a biomarker for neuroinflammation and glial activation.
Additionally, the data showed minimal effects on glutamate levels in 10 of 18 brain regions, a key observation as the company seeks to maintain neuroprotective benefits while minimizing the potential for excitatory toxicity associated with traditional lithium therapies.
Management emphasized that the current results are qualitative and intended to inform future trial designs.
Statistical confirmation will be required through larger, adequately powered patient studies.
To that end, Alzamend confirmed that expanded clinical trials are already underway to further validate these signals in populations with Alzheimer’s disease and bipolar disorder.
AL001 is designed to provide therapeutic brain concentrations of lithium at lower total systemic doses than currently available formulations, potentially reducing the risk of renal and thyroid toxicity.
The company believes this targeted approach could broaden the clinical utility of lithium, which remains a gold standard for mood stabilization but is often limited by its narrow therapeutic window.